US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
CAMBRIDGE, Mass. - MetaVia Inc. (NASDAQ:MTVA), a biotech firm specializing in cardiometabolic diseases with a market capitalization of $15.92 million, today disclosed positive outcomes from its Phase 1 clinical trial of DA-1726, a novel drug candidate for obesity treatment. The company’s stock has surged 34.8% over the past week following these developments, according to InvestingPro data. The 4-week multiple ascending dose (MAD) Part 2 study showed promising safety, tolerability, and clinical activity at a 32 mg dosage.
The trial involved 36 subjects and demonstrated a maximum body weight reduction of 6.3% and an average reduction of 4.3% by Day 26, with a p-value of 0.0005, indicating statistical significance. Additionally, the study reported a maximum waist circumference decrease of 3.9 inches and an average reduction of 1.6 inches by Day 33. These results suggest a strong efficacy signal for the drug, which is designed to target both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). While the clinical results are promising, InvestingPro analysis shows the company is quickly burning through cash, with negative EBITDA of $28.79 million in the last twelve months.
Despite the occurrence of mild gastrointestinal (GI) adverse events in four out of six subjects receiving the 32 mg dose, there were no treatment-related discontinuations or serious adverse events. The study also noted a lowering of fasted glucose levels, with a mean reduction of 5.3 mg/dL and a maximum reduction of 18 mg/dL at Day 26, hinting at the drug’s potential application for Type 2 Diabetes and obese MASH patients.
MetaVia’s President and CEO, Hyung Heon Kim, highlighted the compound’s potential as a "best-in-class obesity drug" and its promising tolerability compared to other treatments. The company plans to further investigate DA-1726’s safety and efficacy in a Phase 1 Part 3 study, targeting patients who discontinued Wegovy® early due to tolerability issues. Analyst price targets for MTVA range from $6 to $23, suggesting significant upside potential from the current price of $1.84. Get access to more detailed financial insights and 12 additional ProTips with InvestingPro.
The drug’s pharmacokinetic results supported the proposed weekly dosing, and no significant cardiovascular signals were observed. The next phase of the study will also explore the maximum tolerated dose by adding additional cohorts.
This report is based on a press release statement from MetaVia Inc. and does not endorse the company’s claims. The information presented is intended to provide an overview of the clinical trial’s findings and does not suggest broader industry impacts or trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.